The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2025 | Treating patients with NSCLC who progress on ROS1 inhibitors
Misako Nagasaka, MD, UCI Health Chao Family Comprehensive Cancer Center, Orange, CA, gives an overview of treatment options for patients with non-small cell lung cancer (NSCLC) progressing on current ROS1 inhibitors. Emerging compounds like repotrectinib and NVL-520, as well as the continued efficacy of TRK inhibitors in combination with chemotherapy are under investigation. This interview took place at the European Lung Cancer Congress (ELCC) 2025 in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
It is a very exciting field. As you just saw, the data of repotrectinib is coming out. And also, there is another compound, NVL-520, which is in clinical trials at this time. And the drug does show promising efficacy as well as safety. So we would like to see those come out. And otherwise, I believe continuation of the TRK inhibitor and adding chemotherapy would be a good option as well...
It is a very exciting field. As you just saw, the data of repotrectinib is coming out. And also, there is another compound, NVL-520, which is in clinical trials at this time. And the drug does show promising efficacy as well as safety. So we would like to see those come out. And otherwise, I believe continuation of the TRK inhibitor and adding chemotherapy would be a good option as well.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
